Related Experiment Video
Updated: Jul 10, 2026

A Fluorescence Microscopy Assay for Monitoring Mitophagy in the Yeast Saccharomyces cerevisiae
Published on: July 18, 2011
Microencapsulation of Monascus Red Pigment Using Saccharomyces cerevisiae Ghosts: Process Optimization and
Mohammed S Khalil1, Shaimaa O Makled2, Nefertiti El-Nikhely1,3
1Department of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt.
Abstract:
Monascus red pigment (MRP) is a highly pigmented microbial secondary metabolite having a therapeutic potential, which can be further enhanced through incorporation into various drug carriers. In this study, MRP produced by Monascus purpureus ATCC16436 was microencapsulated using Saccharomyces cerevisiae (S. cerevisiae) ghosts (ScGs) as a biocarrier, resulting in an innovative bioformulation that integrates the properties of both components. Morphological analysis using light, electron, and confocal microscopy confirmed successful evacuation of S. cerevisiae cells, generating ScGs with a well-preserved three-dimensional structure. The ghosts showed a relatively large internal volume (~ 26 µm3) surrounded by intact, negatively charged cell walls with distinct pores that facilitated the discharge of intracellular contents. Optimization of the microencapsulation process using a Box-Behnken experimental design (BBD) and response surface methodology (RSM) considering temperature, MRP concentration, shaking speed, and incubation time as independent variables, yielded an optimal formulation with a loading efficiency of 61.4 ± 2.3% at 25 °C, 300 mg/mL MRP, 125 rpm shaking rate, and 90 min incubation time. Digital, light, electron, and differential interference contrast (DIC) confocal microscopy confirmed dense MRP encapsulation, with uniform distribution of the pigment throughout the ScGs. The microencapsulated MRP demonstrated a biphasic sustained release profile in PBS (pH 7.4) containing 1.6% Tween 80. In terms of bioactivity, microencapsulation enhanced MRP cytotoxicity against the A549 lung cancer cell line (IC20 > 40, 10 and 3 µg/mL for ScGs, MRP and MRP-ScGs, respectively), consistent with increased cellular uptake observed via confocal microscopy. The MRP-ScGs represent a promising bio-microcapsule platform for biomedical applications, offering structural stability and enhanced therapeutic potential. Additionally, in silico bioinformatic analysis predicted multiple molecular targets associated with vital cellular functions, further supporting their potential in targeted drug delivery.
Insights
Monascus red pigment (MRP) was microencapsulated using yeast cell ghosts (ScGs) for enhanced drug delivery. This novel bioformulation improved MRP
Area of Science:
- Biomaterials Science
- Microbiology
- Drug Delivery Systems
Background:
- Monascus red pigment (MRP) possesses therapeutic potential but requires improved delivery methods.
- Microbial secondary metabolites offer opportunities for novel therapeutic agents.
- Saccharomyces cerevisiae ghosts (ScGs) are a viable biocarrier for encapsulating bioactive compounds.
Purpose of the Study:
- To develop and optimize a microencapsulation technique for Monascus red pigment (MRP) using Saccharomyces cerevisiae ghosts (ScGs).
- To characterize the resulting MRP-ScGs bioformulation and evaluate its drug release profile.
- To assess the enhanced bioactivity and cellular uptake of microencapsulated MRP for potential biomedical applications.
Main Methods:
- Microencapsulation of MRP within S. cerevisiae ghosts.
- Morphological characterization using light, electron, and confocal microscopy.
- Optimization of microencapsulation parameters using Box-Behnken design (BBD) and response surface methodology (RSM).
- Drug release studies in phosphate-buffered saline (PBS) with Tween 80.
- Cytotoxicity assays against A549 lung cancer cells.
- In silico bioinformatic analysis for target prediction.
Main Results:
- Successfully generated S. cerevisiae ghosts (ScGs) with preserved structure and suitable internal volume for microencapsulation.
- Optimized microencapsulation yielded a loading efficiency of 61.4% under specific conditions (25°C, 300 mg/mL MRP, 125 rpm, 90 min).
- Microencapsulated MRP (MRP-ScGs) exhibited a biphasic sustained release profile and enhanced cytotoxicity against A549 lung cancer cells compared to free MRP.
- Confocal microscopy confirmed increased cellular uptake of MRP-ScGs, correlating with enhanced bioactivity.
Conclusions:
- MRP-ScGs represent a promising bio-microcapsule platform for biomedical applications, offering structural stability.
- The microencapsulation process significantly enhanced the therapeutic potential and cellular uptake of Monascus red pigment.
- In silico analysis suggests potential for targeted drug delivery applications of MRP-ScGs.
Related Concept Videos
Microbes in Food Production
Microbes in Beverage Production
Bioreactor Controls-III
Production of Alcohol

